Advances in ocular drug delivery: Emphasis on the posterior segment

Expert Opinion on Drug Delivery

Volumn 11, Issue 10, 2014, Pages 1647-1660

  Kang Mieler, Jennifer J ^a   Osswald, Christian R ^a   Mieler, William F ^b  

^a Illinois Institute of Technology   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anterior segment delivery; Drug delivery; Eye; Posterior segment delivery

Indexed keywords

ANTIINFECTIVE AGENT; BEVACIZUMAB; CORTICOSTEROID; CYCLODEXTRIN DERIVATIVE; DEXAMETHASONE; EMIXUSTAT; EYE DROPS; MIDOSTAURIN; OTX MP; OTX TP 2; PHOSPHOTRANSFERASE INHIBITOR; PRODRUG; PROSTAGLANDIN; PROTEIN KINASE C; RANIBIZUMAB; UNCLASSIFIED DRUG; VERTEPORFIN; DRUG;

ANTERIOR EYE SEGMENT; CELL ENCAPSULATION; CONTACT LENS; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HYDROGEL; IMPLANT; INTRAOCULAR DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; INTRAVITREAL IMPLANT; IONTOPHORESIS; MICROCATHETER; MICRONEEDLE; MULTICENTER STUDY (TOPIC); NONHUMAN; PERIOCULAR DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; POSTERIOR EYE SEGMENT; PUNCTUM PLUG; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPRACHOROIDAL DRUG ADMINISTRATION; SYSTEMIC THERAPY; TOPICAL DRUG ADMINISTRATION; ANIMAL; DRUG EFFECTS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; POSTERIOR EYE SEGMENT;

EID: 84907204322     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.935338     Document Type: Review

References (99)

1. Kokate A, Marasanapalle VP, Jasti BR, et al Design of Controlled Release Drug Delivery Systems: Physiological and Biochemical Barriers to Drug Delivery. McGraw-Hill Professional, New York; 2006
2. Ravivarapu H, Mahalingam R, Jasti BR. Design of controlled release drug delivery systems: Biodegradable polymeric delivery systems. McGraw-Hill Professional, New York; 2006
3. Janoria KG, Gunda S, Boddu SH, et al. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2004;4:371-88
4. Yasukawa T, Ogura Y, Tabata Y, et al. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 2004;23:253-81
5. Campochiaro P. Retinal and choroidal neovascularization. J Cell Physiol 2000;184:201-10
6. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Twoyear results of the ANCHOR study. Ophthalmology 2009;116:57-65
7. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009;29:875-912
8. Kang-Mieler JJ, Kiernan DF, Mieler WF. Duane's ophthalmology: Drug delivery to the posterior segment. Lippincott Williams & Wilkins, Philadelphia; 2011
9. Hughes PM, Olejnik O, Chang-Lin JE, et al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005;57:2010-32
10. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: Challenges and opportunities. Expert Opin Biol Ther 2003;3:45-56
11. Lee VHL, Robinson JR. Topical ocular drug delivery: Recent developments and future challenges. J Ocul Pharmacol Ther 1986;2:67-108
12. Loftssona T, Järvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 1999;36:59-79
13. Sigurdsson HH, Konrá-sdóttir F, Loftsson T, et al. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand 2007;85:598-602
14. Babizhayev MA. Current ocular drug delivery challenges for n-Acetylcarnosine: Novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Recent Pat Drug Deliv Formul 2009;3:229-65
15. Phan CM, Subbaraman L, Jones L. Contact lenses for antifungal ocular drug delivery: A review. Expert Opin Drug Deliv 2014;11:537-46
16. Tanito M, Kara K, Takai Y, et al. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci 2011;52:7944-8
17. College of Medicine; King Saud University. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema (DECEDE). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01523314 [Cited 12 March 2014] NLM Identifier NCT01523314
18. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol 2005;50:167-82
19. Shirasaki Y. Molecular design for enhancement of ocular penetration. J Pharm Sci 2008;97:2462-96
20. Rodriguez-Aller M, Kaufmann B, Guillarme D, et al. In vivo characterisation of a novel water-soluble cyclosporine A prodrug for the treatment of dry eye disease. Eur J Pharm Biopharm 2012;80:544-52
21. Bochot A, Mashhour B, Puisieux F, et al. Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms. J Drug Target 1998;6:309-13
22. Davis BM, Normando EM, Guo L, et al. Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-Associated liposomes. Small 2014;10:1575-84
23. Oling F, Santos JS, Govorukhina N, et al. Structure of membrane-bound annexin A5 trimers: A hybrid cryo-EM-x-ray crystallography study. J Mol Biol 2000;304:561-73
24. Tajika T, Isowaki A, Sakaki H. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther 2011;27:43-9
25. Nakano Goto S, Yamamoto T, Kirii E, et al. Treatment of diffuse diabetic macular oedema using steroid eye drops. Acta Ophthalmol 2012;90:629-32
26. Nakano S, Yamamoto T, Kirii E, et al. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2010;248:805-10
27. Ocular Therapeutix, Inc. Phase II study evaluating safety/efficacy of OTX-DP for treatment of ocular inflammation and pain after cataract surgery. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01666210 [cited 25 March 2014] NLM Identifier NCT01666210
28. Dexamethasone Punctum Plug. Ocular Therapeutix, Inc., Bedford, MA; 2014. Available from: Www.ocutx.com/pipeline/dexamethasone-punctum-plug [Last accessed 29 April 2014]
29. Endl MJ, Levenson JH, Walters TR, et al. Multi-center evaluation of safety and efficacy of sustained-release dexamethasone after cataract surgery, in: Intraocular Surgery Medications. The Annual ASCRS and ASOA Symposium and Congress; 27 April 2014; Boston, MA 30. Pipeline. Ocular Therapeutix, Inc., Bedford, MA; 2014. Available from: Www.ocutx.com/pipeline [Last accessed 29 April 2014]
30. Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci 2009;50:3346-52
31. Hu X, Hao L, Wang H, et al. Hydrogel contact lens for extended delivery of ophthalmic drugs. Int J Polym Sci 2011;2011:1-9
32. Fenton C, Perry CM. Verteporfin: A review of its use in the management of subfoveal choroidal neovascularization. Drug Aging 2006;23:421-45
33. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: Threeyear results of an open-label extension of 2 randomized clinical trials-TAP report no. 5. Arch Ophthalmol 2002;120:1307-14
34. Pachydaki S, Sobrin L, Miller JW. Photodynamic therapy and combination treatments. Int Ophthalmol Clin 2007;47:95-115
35. Campochiaro PA; The C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004;45:922-31
36. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003;44:4989-93
37. Golczak M, Maeda A, Bereta G, et al. Metabolic basis of visual cycle inhibition by retinoid and nonretinoid compounds in the vertebrate retina. J Biol Chem 2008;283:9543-54
38. Akula JD, Hansen RM, Tzekov R, et al. Visual cycle modulation in neurovascular retinopathy. Exp Eye Res 2010;91:153-61
39. Kubota R, Al-Fayoumi S, Mallikaarjun S, et al. Phase 1, doseranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina 2014;34:603-9
40. Ben-Shabat S, Parish CA, Vollmer HR, et al. Biosynthetic studies of A2E, a major fluorophore of retinal pigment epithelial lipofuscin. J Biol Chem 2002;277:7183-90
41. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 2004;1:99-114
42. Yang C, Tirucherai GS, Mitra AK. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin Biol Ther 2001;1:159-75
43. Kim S, Lutz R, Wang N, et al. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 2007;39:244-54
44. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transcleral iontophoresis. Adv Drug Deliv Rev 2005;57:2063-79
45. Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, et al. Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release 2005;106:386-90
46. Cohen AE, Assang C, Patane MA, et al. Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology 2012;119:66-73
47. Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: Results of a randomized clinical trial. Clin Ophthalmol 2011;5:633-43
48. Department of Ophthalmology and Epidemiology; University of Pennsylvania. Iontophoresis delivery of dexamethasone phosphate for noninfectious, non-necrotizing anterior scleritis, phase 1 dose-varying study. In: Clinical Trials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01059955 [Cited 21 March 2014] NLM Identifier NCT01059955
49. Pipeline. Eyegate Pharmaceuticals, Inc., Waltham, MA. 2013. Available from: Www.eyegatepharma.com/therapeutics/pipeline5.html [Last accessed 29 April 2014]
50. Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. In: Development of Sustained Delivery Lucentis. Genentech, Inc., South San Francisco, CA. 2012. Available from: Www.gene.com/media/press-releases/13808/2012-01-13/genentech-Announces-first-milestonepaym [Last accessed 21 March 2014]
51. Forsight Vision4. Preliminary safety and efficacy of the PDS-1.0 in patients with neovascular age related macular degeneration (AMD). In: ClinicalTrials. gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials. gov/ct2/show/NCT01186432 [Cited 21 Mar 2014] NLM Identifier NCT01186432
52. Weiner AL, Sinnett K, Johnson S. Tack for intraocular drug delivery and method for inserting and removing same. US5466233; 1995
53. Alster Y, Herlin L, Lazar M, et al. Intraocular penetration of vancomycin eye drops after application to the medial canthus with closed lids. Br J Ophthalmol 2000;84:300-2
54. Santen Pharmaceutical Co., Ltd. Efficacy and safety of betamethasone microsphere in patients with diabetic macular wdema (TSUBASA). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01411254 [Cited 25 Mar 2014] NLM Identifier NCT01411254
55. Santen Pharmaceutical Co., Ltd. Efficacy and safety of betamethasone microsphere in patients with macular edema following branch retinal vein occlusion (HIKARI). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01512901 [Cited 25 Mar 2014] NLM Identifier NCT01512901
56. Novack GD. Conducting clinical trials: Even more challenges. Ocul Surf 2008;6:99-101
57. Chroniject-Technology. Oakwood Laboratories, LLC., Oakwood Village, OH, 2014. Available from: Www.oakwoodlabs.com/technology/index. php [Last accessed 25 March 2014]
58. Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: Circumferential viscodilation and tensioning of Schlemm's canal using a flexible microcatheter for the treatment of openangle glaucoma in adults: Interim clinical study analysis. J Cataract Refract Surg 2007;33:1217-26
59. Olsen TW, Feng X, Wabner K, et al. Cannulation of the suprachoroidal space: A novel drug delivery methodology to the posterior segment. Am J Ophthalmol 2006;142:777-87
60. Olsen TW, Feng X, Wabner K, et al. Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model. Invest Ophthalmol Vis Sci 2011;52:4749-56
61. Tetz M, Rizzo S, Augustin AJ. Safety of submacular suprachoroidal drug administration via a microcatheter: Retrospective analysis of European treatment results. Ophthalmologica 2012;227:183-9
62. Rizzo S, Ebert FG, Bartolo ED, et al. Suprachoroidal drug infusion for the treatment of severe subfoveal hard exudates. Retina 2012;32:776-84
63. Janssen Research & Development, LLC. A safety study of CNTO 2476 in patients with age-related macular degeneration. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials. gov/ct2/show/NCT01226628 [Cited 29 April 2014] NLM Identifier NCT01226628
64. Patel SR, Lin AS, Edelhauser HF, et al. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res 2011;28:166-76
65. Bourges J, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: Therapeutic applications. Adv Drug Deliv Rev 2006;58:1182-202
66. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1419-31
67. Brechner RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 Medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151:887-95
68. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2012;119:1388-98
69. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28:207-14
70. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48
71. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular agerelated macular degeneration. Ophthalmology 2014;121:193-201
72. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-37
73. Bayer. VEGF trap-eye in vision impairment due to DME (VIVIDDME). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials. gov/ct2/show/NCT01331681 [Cited 29 April 2014] NLM Identifier NCT01331681
74. Regeneron Pharmaceuticals. Study of intravitreal administration of VEGF trap-eye (BAY86-5321) in patients with diabetic macular edema (VISTA DME). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01363440 [Cited 29 April 2014] NLM Identifier NCT01363440
75. Bayer. Efficacy and safety of VEGF trap eye in diabetic macular edema (DME) with central involvement (VIVID EAST). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01783886 [Cited 29 April 2014] NLM Identifier NCT01783886
76. Fovista-. Ophtotech Co. New York, NY; 2014. Available from: Www.ophthotech.com/productcandidates/fovista/[Last accessed 24 March 2014]
77. Ophthotech Corp. A safety and efficacy study of E10030 (anti-PDGF pegylated aptamer) plus Lucentis for neovascular age-related macular degeneration. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01089517 [Cited 24 March 2014] NLM Identifier NCT01089517
78. Ophthotech Corp. A phase 3 safety and efficacy study of Fovista-(E10030) intravitreous administration in combination with Lucentis-compared to Lucentis-monotherapy. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01940900 [Cited 24 March 2014] NLM Identifier NCT01940900
79. Ophthotech Corp. A phase 3 safety and efficacy study of Fovista-(E10030) intravitreous administration in combination with either Avastin-or Eylea-compared to Avastin-or Eylea-monotherapy. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US). 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01940887 [Cited 24 March 2014] NLM Identifier NCT01940887
80. Fung AE. A novel sustained-release intravitreal drug delivery system for retinal vascular disease. Retin Today 2010;51-3
81. Fung AE. One-year safety and efficacy of an injectable, sustained-delivery, liquid steroid for treatment of macular edema due to retinal vein occlusion. 20 February 2010; Angiogenesis 2010: Clinical Trials, Miami, FL
82. University of Illinois-Chicago Eye and Ear Infirmary. 20089 TA+Lucentis combo intravitreal injections for treatment of neovascular age-related macular degeneration (AMD) (20089/Combo). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Www.clinicaltrials.gov/ct2/show/NCT01175395 [Cited 17 Mar 2014] NLM Identifier NCT01175395
83. IBI-10090. Icon Bioscience, Inc., Sunnyvale, CA; 2014. Available from: Www.iconbioscience.com/ibi-10090 [Last accessed 17 March 2014]
84. Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1999;127:288-93
85. Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert-intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-75
86. Emerich DF, Thanos C. NT-501: An ophthalmic implant of polymerencapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 2008;10:506-15
87. Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 2006;6:717-26
88. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006;103:3896-901
89. ECT Pipeline. Neurotech Pharmaceuticals, Inc., Cumberland, RI; 2012. Available from: Www.neurotechusa. com/ect-pipeline.html [Last accessed 19 March 2014]
90. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-Term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;112:1192-8
91. Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg. Bausch & Lomb, Inc., Rochester, NY; 2014. Available from: Www.bausch.com/en/ecp/our-products/rx-pharmaceuticals/rxpharmaceuticals-ecp/retisert/[Last accessed 18 March 2014]
92. Kane FE, Burdan J, Cutino A, Green KE. Iluvien-: A new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5:1039-46
93. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17
94. Osswald CR, Kang-Mieler JJ. Development of an extended release drug delivery system to treat choroidal neovascularization, in: Materials for Biomedical Applications II. 6th Annual AIChE Midwest Regional Conference; 11 March 2014; Chicago, IL, USA
95. Osswald CR, Kang-Mieler JJ. Ovalbumin as a model protein for ranibizumab in a poly(lactic-co-glycolic) acid microsphere drug delivery system, in: Physiology/Pharmacology. ARVO Annual Meeting. Invest Ophthalmol Vis Sci 4 May 2014; Orlando, FL, USA . Controlled release of protein from microspheres beyond 5 months.
96. Drapala PW, Brey EM, Mieler WF, et al. Role of thermo-responsiveness and poly(ethylene glycol) diacrylate cross-link density on protein release from poly(Nisopropylacrylamide) hydrogels. J Biomater Sci Polym Ed 2011;22:59-75
97. Turturro SB, Guthrie MJ, Appel AA. The effects of cross-linked thermoresponsive PNIPAAm-based hydrogel injection on retinal function. Biomaterials 2011;32:3620-6
98. Drapala PW, Jiang B, Chiu YC, et al. The effect of glutathione as chain transfer agent in PNIPAAm-based thermo-responsive hydrogels for controlled release of proteins. Pharm Res 2014;31:742-53
99. Guthrie MJ, Osswald CR, Valio NL, et al. Objective area measurement technique for choroidal neovascularization. Microvasc Res 2014;91:1-7